173 related articles for article (PubMed ID: 27910741)
41. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery.
Eloy JO; Claro de Souza M; Petrilli R; Barcellos JP; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2014 Nov; 123():345-63. PubMed ID: 25280609
[TBL] [Abstract][Full Text] [Related]
42. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.
Gilabert-Oriol R; Chernov L; Anantha M; Dragowska WH; Bally MB
Drug Deliv Transl Res; 2017 Aug; 7(4):544-557. PubMed ID: 28432657
[TBL] [Abstract][Full Text] [Related]
43. Multi-functional vesicles for cancer therapy: The ultimate magic bullet.
Tavano L; Muzzalupo R
Colloids Surf B Biointerfaces; 2016 Nov; 147():161-171. PubMed ID: 27500359
[TBL] [Abstract][Full Text] [Related]
44. New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy.
Gardikis K; Hatziantoniou S; Bucos M; Fessas D; Signorelli M; Felekis T; Zervou M; Screttas CG; Steele BR; Ionov M; Micha-Screttas M; Klajnert B; Bryszewska M; Demetzos C
J Pharm Sci; 2010 Aug; 99(8):3561-71. PubMed ID: 20564386
[TBL] [Abstract][Full Text] [Related]
45. [Nanostructured liposomal systems as transport agents for anticancer drugs].
Baryshnikov AIu
Vestn Ross Akad Med Nauk; 2012; (3):23-31. PubMed ID: 22712271
[TBL] [Abstract][Full Text] [Related]
46. Liposomal Drug Delivery System for Cancer Therapy: Advancement and Patents.
Jha S; Sharma PK; Malviya R
Recent Pat Drug Deliv Formul; 2016; 10(3):177-183. PubMed ID: 27712569
[TBL] [Abstract][Full Text] [Related]
47. [Methods to increase the encapsulation efficiency for liposomal drugs].
Kaszás N; Budai M; Budai L; Gróf P; Zimmer A; Klebovich I
Acta Pharm Hung; 2008; 78(2):69-74. PubMed ID: 18807386
[TBL] [Abstract][Full Text] [Related]
48. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.
Immordino ML; Dosio F; Cattel L
Int J Nanomedicine; 2006; 1(3):297-315. PubMed ID: 17717971
[TBL] [Abstract][Full Text] [Related]
49. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape.
Zylberberg C; Matosevic S
Drug Deliv; 2016 Nov; 23(9):3319-3329. PubMed ID: 27145899
[TBL] [Abstract][Full Text] [Related]
50. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
51. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
52. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
53. Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice.
Xing J; Qi X; Jiang Y; Zhu X; Zhang Z; Qin X; Wu Z
Pharm Dev Technol; 2015 Nov; 20(7):812-819. PubMed ID: 24909735
[TBL] [Abstract][Full Text] [Related]
54. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
55. Topotecan-loaded mesoporous silica nanoparticles for reversing multi-drug resistance by synergetic chemoradiotherapy.
Shen B; Zhao K; Ma S; Yuan D; Bai Y
Chem Asian J; 2015 Feb; 10(2):344-8. PubMed ID: 25413970
[TBL] [Abstract][Full Text] [Related]
56. Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications.
Rajpoot K
Curr Cancer Drug Targets; 2020; 20(4):271-287. PubMed ID: 31951180
[TBL] [Abstract][Full Text] [Related]
57. A review on novel vesicular drug delivery: proniosomes.
Yasam VR; Jakki SL; Natarajan J; Kuppusamy G
Drug Deliv; 2014 Jun; 21(4):243-9. PubMed ID: 24128089
[TBL] [Abstract][Full Text] [Related]
58. Factors affecting microencapsulation of drugs in liposomes.
Kulkarni SB; Betageri GV; Singh M
J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
[TBL] [Abstract][Full Text] [Related]
59. Enzymatic action of phospholipase A₂ on liposomal drug delivery systems.
Hansen AH; Mouritsen OG; Arouri A
Int J Pharm; 2015 Aug; 491(1-2):49-57. PubMed ID: 26056930
[TBL] [Abstract][Full Text] [Related]
60. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
